Yili Chuanning BiotechnologyLtd Future Growth
Future criteria checks 1/6
Yili Chuanning BiotechnologyLtd is forecast to grow earnings and revenue by 14.9% and 10% per annum respectively. EPS is expected to grow by 15.6% per annum. Return on equity is forecast to be 17.7% in 3 years.
Key information
14.9%
Earnings growth rate
15.6%
EPS growth rate
| Biotechs earnings growth | 43.3% |
| Revenue growth rate | 10.0% |
| Future return on equity | 17.7% |
| Analyst coverage | Low |
| Last updated | 22 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 7,119 | 1,910 | N/A | 2,281 | 3 |
| 12/31/2025 | 6,543 | 1,700 | N/A | 2,037 | 3 |
| 12/31/2024 | 5,876 | 1,437 | N/A | 1,478 | 3 |
| 9/30/2024 | 5,698 | 1,376 | 844 | 1,065 | N/A |
| 6/30/2024 | 5,602 | 1,316 | 742 | 1,029 | N/A |
| 3/31/2024 | 5,077 | 1,118 | 1,214 | 1,608 | N/A |
| 12/31/2023 | 4,823 | 941 | 947 | 1,292 | N/A |
| 9/30/2023 | 4,462 | 719 | 1,693 | 1,898 | N/A |
| 6/30/2023 | 4,254 | 565 | 1,544 | 1,668 | N/A |
| 3/31/2023 | 4,093 | 486 | 601 | 643 | N/A |
| 1/1/2023 | 3,821 | 412 | 644 | 692 | N/A |
| 9/30/2022 | 3,634 | 272 | 127 | 223 | N/A |
| 3/31/2022 | 3,345 | 154 | 922 | 977 | N/A |
| 1/1/2022 | 3,232 | 111 | 751 | 803 | N/A |
| 12/31/2020 | 3,649 | 229 | 561 | 650 | N/A |
| 12/31/2019 | 3,143 | 91 | -212 | -147 | N/A |
| 12/31/2018 | 3,349 | 390 | 280 | 310 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301301's forecast earnings growth (14.9% per year) is above the savings rate (2.8%).
Earnings vs Market: 301301's earnings (14.9% per year) are forecast to grow slower than the CN market (26.3% per year).
High Growth Earnings: 301301's earnings are forecast to grow, but not significantly.
Revenue vs Market: 301301's revenue (10% per year) is forecast to grow slower than the CN market (13.9% per year).
High Growth Revenue: 301301's revenue (10% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301301's Return on Equity is forecast to be low in 3 years time (17.7%).